Clinical Trial Detail

NCT ID NCT03701282
Title Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

CLL/SLL

chronic lymphocytic leukemia

Therapies

Ibrutinib + Obinutuzumab

Ibrutinib + Obinutuzumab + Venetoclax

Age Groups: adult senior

No variant requirements are available.